Although transgenic or pharmacologic mTOR inhibition alleviated ADPKD in experimental animal studies, the clinical success of mTOR inhibitors (sirolimus and everolimus) was rather limited in ADPKD patients (145–148). The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.